Skip to main content
. 1999 Oct 25;1999(4):CD003274. doi: 10.1002/14651858.CD003274

Comparison 7. BUD v Placebo: parallel studies, not on oral steroids: all doses.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 FEV1 (% predicted) 8 217 Mean Difference (IV, Fixed, 95% CI) ‐3.70 [‐7.09, ‐0.31]
1.1 400 mcg/day or less 3 71 Mean Difference (IV, Fixed, 95% CI) ‐2.09 [‐7.33, 3.16]
1.2 500‐800 mcg/day 5 146 Mean Difference (IV, Fixed, 95% CI) ‐4.86 [‐9.31, ‐0.42]
1.3 1000 mcg/day or greater 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 FEV1 (litres) 4 103 Mean Difference (IV, Fixed, 95% CI) 0.07 [‐0.25, 0.40]
2.1 400 mcg/day or less 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 500‐800 mcg/day 2 47 Mean Difference (IV, Fixed, 95% CI) 0.14 [‐0.27, 0.55]
2.3 1000 mcg/day or greater 2 56 Mean Difference (IV, Fixed, 95% CI) ‐0.04 [‐0.57, 0.49]
3 Change in FEV1 (litres) compared to baseline 2 99 Mean Difference (IV, Fixed, 95% CI) ‐0.20 [‐0.33, ‐0.07]
3.1 400 mcg/day or less 2 99 Mean Difference (IV, Fixed, 95% CI) ‐0.20 [‐0.33, ‐0.07]
3.2 500‐800 mcg/day 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 1000 mcg/day or greater 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Morning PEFR (L/min) 3 94 Mean Difference (IV, Fixed, 95% CI) ‐30.86 [‐66.51, 4.79]
4.1 400 mcg/day or less 1 17 Mean Difference (IV, Fixed, 95% CI) ‐29.46 [‐107.88, 48.96]
4.2 500‐800 mcg/day 2 77 Mean Difference (IV, Fixed, 95% CI) ‐31.22 [‐71.25, 8.80]
4.3 1000 mcg/day or greater 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Change in morning PEFR (L/min) compared to baseline 6 469 Mean Difference (IV, Fixed, 95% CI) ‐28.92 [‐36.11, ‐21.74]
5.1 400 mcg/day or less 4 404 Mean Difference (IV, Fixed, 95% CI) ‐26.91 [‐34.42, ‐19.41]
5.2 500‐800 mcg/day 2 65 Mean Difference (IV, Fixed, 95% CI) ‐51.34 [‐76.38, ‐26.30]
5.3 1000 mcg/day or greater 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Change in evening PEFR (L/min) compared to baseline 6 469 Mean Difference (IV, Fixed, 95% CI) ‐20.64 [‐28.29, ‐13.00]
6.1 400 mcg/day or less 4 404 Mean Difference (IV, Fixed, 95% CI) ‐16.03 [‐24.53, ‐7.54]
6.2 500‐800 mcg/day 2 65 Mean Difference (IV, Fixed, 95% CI) ‐40.33 [‐57.88, ‐22.78]
6.3 1000 mcg/day or greater 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Change in daytime use of short‐acting beta2 agonist (puffs/daytime) compared to baseline 5 480 Mean Difference (IV, Fixed, 95% CI) ‐0.43 [‐0.80, ‐0.06]
7.1 400 mcg/d or less 5 480 Mean Difference (IV, Fixed, 95% CI) ‐0.43 [‐0.80, ‐0.06]
7.2 500‐800 mcg/day 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 1000 mcg/day or greater 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Change in night‐time use of short‐acting beta2 agonist (puffs/night) compared to baseline 3 304 Mean Difference (IV, Fixed, 95% CI) ‐0.71 [‐1.09, ‐0.33]
8.1 400 mcg/day or less 3 304 Mean Difference (IV, Fixed, 95% CI) ‐0.71 [‐1.09, ‐0.33]
8.2 500‐800 mcg/day 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.3 1000 mcg/day or greater 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Methacholine bronchial responsiveness (log 10 values) 3 76 Mean Difference (IV, Fixed, 95% CI) ‐0.04 [‐0.29, 0.21]
9.1 400 mcg/day or less 1 22 Mean Difference (IV, Fixed, 95% CI) 0.04 [‐0.31, 0.39]
9.2 500‐800 mcg/day 2 54 Mean Difference (IV, Fixed, 95% CI) ‐0.12 [‐0.48, 0.23]
9.3 1000 mcg/day or greater 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Histamine bronchial responsiveness (log 10 values) 2 80 Mean Difference (IV, Fixed, 95% CI) ‐0.40 [‐0.70, ‐0.11]
10.1 400 mcg/day or less 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 500‐800 mcg/day 2 80 Mean Difference (IV, Fixed, 95% CI) ‐0.40 [‐0.70, ‐0.11]
10.3 1000 mcg/day or greater 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Withdrawal due to asthma exacerbation (No. of patients) 17 910 Risk Ratio (M‐H, Fixed, 95% CI) 0.17 [0.09, 0.33]
11.1 400 mcg/day or less 7 551 Risk Ratio (M‐H, Fixed, 95% CI) 0.21 [0.08, 0.57]
11.2 500‐800 mcg/day 9 341 Risk Ratio (M‐H, Fixed, 95% CI) 0.14 [0.05, 0.35]
11.3 1000 mcg/day or greater 1 18 Risk Ratio (M‐H, Fixed, 95% CI) 0.33 [0.02, 7.24]
12 Requirement for one or more courses of oral steroid for asthma exacerbation (No. of patients) 5 255 Risk Ratio (M‐H, Fixed, 95% CI) 0.34 [0.19, 0.59]
12.1 400 mcg/day or less 2 69 Risk Ratio (M‐H, Fixed, 95% CI) 0.51 [0.18, 1.40]
12.2 500‐800 mcg/day 1 116 Risk Ratio (M‐H, Fixed, 95% CI) 0.29 [0.14, 0.57]
12.3 1000 mcg/day or greater 2 70 Risk Ratio (M‐H, Fixed, 95% CI) 0.33 [0.04, 2.94]
13 Oropharyngeal side effects (No. of patients) 5 275 Risk Ratio (M‐H, Fixed, 95% CI) 0.81 [0.53, 1.23]
13.1 400 mcg/day or less 3 140 Risk Ratio (M‐H, Fixed, 95% CI) 0.97 [0.51, 1.83]
13.2 500‐800 mcg/day 2 135 Risk Ratio (M‐H, Fixed, 95% CI) 0.72 [0.41, 1.26]
13.3 1000 mcg/day or greater 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]